The target-hypertension (Target-HTN) trial investigated the efficacy and safety of lorundrostat, an aldosterone synthase inhibitor, as an antihypertensive. Cohort 1 of the trial includes patients with suppressed plasma renin activity and elevated aldosterone levels. Lorundrostat doses of 100 mg and 50 mg daily significantly decreased systolic blood pressure compared to the placebo group. Cohort 2 also demonstrated a reduction in systolic blood pressure with the 100 mg daily dose of lorundrostat. Lorundrostat is more selective for the inhibition of CYP11B2 versus CYP11B1, which makes it preferable to other aldosterone synthase inhibitors that inhibit cortisol synthesis, such as osilodrostat. Phase 3 trials are needed to validate the safety and efficacy of lorundrostat, and further research should be performed on other selective aldosterone synthase inhibitors such as baxdrostat, dexfadrostat, and BI 690517.

中文翻译：

---

难治性高血压的新兴疗法：Lorundrostat 和相关选择性醛固酮合酶抑制剂的综述。

目标高血压（Target-HTN）试验研究了洛仑司他（一种醛固酮合酶抑制剂）作为抗高血压药物的有效性和安全性。该试验的第一组包括血浆肾素活性受到抑制和醛固酮水平升高的患者。与安慰剂组相比，每天 100 mg 和 50 mg 的 Lorundrostat 剂量可显着降低收缩压。第 2 组还表现出每日 100 毫克剂量的洛仑司他可降低收缩压。与 CYP11B1 相比，Lorundrostat 对 CYP11B2 的抑制更具选择性，这使得它比其他抑制皮质醇合成的醛固酮合酶抑制剂（例如奥西洛司他）更可取。需要进行 3 期试验来验证 lorundrostat 的安全性和有效性，并且应对其他选择性醛固酮合酶抑制剂（例如 baxdrostat、dexfadrostat 和 BI 690517）进行进一步研究。